Episode Details

Hims & Hers completely flipped the script in Q1 2026, eating a massive restructuring loss to dodge mounting legal heat while simultaneously financing a massive global footprint.

In ~10 minutes:

• Torching $33M in compounding drug inventory to evade DOJ scrutiny.

• Why gross margins cratered to 65% despite surging branded Wegovy sales.

• A 969% surge in international revenue ahead of the $1.15B Eucalyptus buyout.

• The $150M microneedle pivot to build a proactive, AI-driven blood testing loop.

Management characterized this dramatic operational reset as a “strategic shift,” but the resulting $92.1 million quarterly net loss sparked a swift 11% after-hours stock selloff. Behind the headline margin pain, the telemedicine platform is actively replacing its highly scrutinized compounded prescriptions with a vertically integrated, globally expanding preventative health empire. 🩸

Hims & Hers Health, Inc. (HIMS) | Q1 FY2026

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.